Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHERGINE vs ERGOLOID MESYLATES
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylergonovine is an ergot alkaloid that acts as a partial agonist at α-adrenergic receptors in the uterine smooth muscle, causing sustained contractions. It also exhibits serotonergic (5-HT2) and dopaminergic activity.
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
Prevention and treatment of postpartum hemorrhage due to uterine atony,Management of incomplete abortion
Treatment of age-related cognitive decline,Dementia (unlabeled use)
0.2 mg intramuscularly or intravenously after delivery of placenta and every 2-4 hours as needed, up to a maximum of 5 doses.
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
Terminal elimination half-life is approximately 2–3 hours in healthy adults; prolonged in hepatic impairment.
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Primarily hepatic via CYP3A4 with significant first-pass metabolism; active metabolite is methylergonovine itself; excreted mainly in bile and urine.
Hepatic metabolism via CYP3A4 primarily; extensive first-pass effect.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Biliary/fecal excretion accounts for ~80% of metabolites.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
Approximately 93% bound, primarily to albumin and alpha-1-acid glycoprotein.
Approximately 90% bound to albumin.
0.6 L/kg (range 0.3–0.8 L/kg), indicating moderate distribution into tissues.
1.5-2 L/kg, indicating extensive tissue distribution.
Oral bioavailability is approximately 10–20% due to extensive first-pass metabolism. Intramuscular administration provides 100% bioavailability.
Oral: less than 10% due to extensive first-pass metabolism.
No specific dose adjustment recommended; use with caution in renal impairment due to risk of hypertension.
Not studied; no specific recommendations. Caution advised in severe renal impairment (GFR <30 m L/min).
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B, use with caution and monitor for signs of toxicity.
Contraindicated in Child-Pugh class C (severe hepatic impairment). Use with caution in Child-Pugh class B; reduce dose by 50%.
Not recommended for pediatric use; safety and efficacy in children have not been established.
Not established; safety and efficacy not determined in pediatric patients.
Use with caution in elderly patients due to increased sensitivity to vasoconstrictive effects and higher risk of hypertension and myocardial ischemia.
Initiate at 1 mg twice daily; titrate slowly. Monitor for orthostatic hypotension and cognitive effects.
Not for use during pregnancy (except during delivery) due to risk of uterine tetany and fetal hypoxia. Contraindicated in patients with hypertension, preeclampsia, or eclampsia due to risk of severe hypertension and stroke.
No FDA black box warning.
Risk of severe hypertension, especially in patients with preeclampsia, eclampsia, or hypertension.,Use with caution in patients with sepsis, hepatic or renal impairment, or coronary artery disease.,May cause ergotism with prolonged use or high doses (symptoms: vasospasm, ischemia).,Monitor blood pressure and uterine response during administration.
Use with caution in patients with hypotension, bradycardia, or history of psychosis; may cause orthostatic hypotension; monitor for signs of ergotism.
Hypersensitivity to ergot alkaloids,Pregnancy (for antepartum use),Hypertension, preeclampsia, or eclampsia,Peripheral vascular disease,Coronary artery disease,Severe hepatic or renal impairment,Sepsis
Hypersensitivity to ergot alkaloids; severe hypotension; acute or chronic psychosis; concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals).
Avoid grapefruit juice as it may increase serum levels of methylergonovine via CYP3A4 inhibition. No specific food restrictions other than avoiding excessive caffeine intake, which may potentiate vasoconstrictive effects.
Avoid grapefruit juice as it may increase drug levels. Limit caffeine intake as it may exacerbate vasoconstrictive effects. Maintain adequate hydration.
Methergine (methylergonovine) is contraindicated in pregnancy due to its oxytocic properties and risk of uterine hyperstimulation, fetal distress, and abortion. First trimester: potential teratogenic effects not well studied; avoid use. Second and third trimesters: can cause abruptio placentae, premature labor, and fetal anoxia. It is FDA Pregnancy Category X.
Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. Second/Third trimester: Contraindicated due to oxytocic effects causing uterine hypertonicity, placental hypoperfusion, and fetal distress. Use only if benefit outweighs risk for life-threatening conditions.
Methylergonovine is excreted into breast milk in small amounts; the milk-to-plasma ratio is approximately 1.0. Adverse effects in nursing infants are rare but may include diarrhea, vomiting, and hypertension. It is generally considered compatible with breastfeeding when used short-term for postpartum hemorrhage. Avoid prolonged use.
Excreted into breast milk; M/P ratio unknown. May suppress prolactin and reduce milk production. Potential for ergotism in neonates (vomiting, diarrhea, convulsions). Contraindicated during breastfeeding.
Not applicable; the drug is contraindicated during pregnancy. No dose adjustments are recommended for use during pregnancy as it should not be used.
No established safe dose in pregnancy. Avoid use. If absolutely necessary, lowest effective dose and shortest duration, but no specific pharmacokinetic data available to guide adjustments.
METHERGINE (methylergonovine) is an ergot alkaloid used primarily for postpartum hemorrhage due to uterine atony. Do not use for routine induction of labor or for threatened abortion. Avoid in patients with hypertension, preeclampsia, coronary artery disease, or severe hepatic/renal disease. Monitor blood pressure closely during administration. Administer intramuscularly for rapid effect; onset is 2-5 minutes. Intravenous administration should be reserved for emergencies due to risk of hypertensive crisis. Contraindicated in pregnancy except immediately after delivery. Drug interactions: avoid concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, macrolides, protease inhibitors) due to risk of ergotism and vasospasm. As of April 2025, there is no generic form; brand METHERGINE only.
Ergoloid mesylates are a mixture of dihydrogenated ergot alkaloids historically used for dementia, though efficacy is unproven. Avoid in patients with psychosis, severe bradycardia, or recent MI. Monitor for ergotism symptoms (vasospasm, ischemia). Not recommended due to lack of evidence.
This medication is used to prevent or treat excessive bleeding after childbirth by causing contractions of the uterus.,Report immediately if you experience severe headache, chest pain, vision changes, muscle cramps, or numbness/tingling in the arms or legs.,Avoid breastfeeding within 8 hours after the last dose if possible; if breastfeeding is necessary, pump and discard for 8 hours to reduce infant exposure.,Do not use this medication if you have uncontrolled high blood pressure, heart disease, or liver/kidney disease.,Avoid alcohol and grapefruit juice while on this medication as they may affect blood levels.,Take this medication exactly as prescribed; do not take double doses if a dose is missed.
Take exactly as prescribed; do not double doses if missed.,Report signs of ergotism: cold/blue fingers/toes, muscle pain, tingling or numbness.,Avoid smoking and caffeine as they may worsen vasoconstriction.,May cause dizziness or fainting; avoid driving until you know how the drug affects you.,Do not use with other ergot alkaloids or triptans.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHERGINE vs ERGOLOID MESYLATES, answered by our medical review team.
METHERGINE is a Ergot Alkaloid Uterotonic that works by Methylergonovine is an ergot alkaloid that acts as a partial agonist at α-adrenergic receptors in the uterine smooth muscle, causing sustained contractions. It also exhibits serotonergic (5-HT2) and dopaminergic activity.. ERGOLOID MESYLATES is a Ergot Alkaloid that works by Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHERGINE and ERGOLOID MESYLATES depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHERGINE is: 0.2 mg intramuscularly or intravenously after delivery of placenta and every 2-4 hours as needed, up to a maximum of 5 doses.. The standard adult dose of ERGOLOID MESYLATES is: Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METHERGINE and ERGOLOID MESYLATES in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METHERGINE is classified as Category C. Methergine (methylergonovine) is contraindicated in pregnancy due to its oxytocic properties and risk of uterine hyperstimulation, fetal distress, and abortion. First trimester: po. ERGOLOID MESYLATES is classified as Category A/B. Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.